Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 58

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 58
---
visors.com</div>

To obtain timely delivery, our stockholders must request the materials no later than five business days prior to the Special Meeting.

You may also obtain additional information about us from documents filed with the SEC by following the instructions in the section entitled “Where You Can Find More Information.”

If you intend to seek redemption of your Iris Class A Common Stock, you will need to send a letter demanding redemption and deliver your stock (either physically or electronically) to our Transfer Agent

<div align='center'>xxiii</div>

TABLE OF CONTENTS

prior to the Special Meeting. If you have questions regarding the certification of your position or delivery of your stock, please contact:

<div align='center'>Continental Stock Transfer & Trust Company 
 1 State Street, 30th Floor 
 New York, New York 10004 
 Attn: Mark Zimkind 
 E-mail: mzimkind@continentalstock.com

xxiv</div>

TABLE OF CONTENTS

#### SUMMARY OF THE PROXY STATEMENT/PROSPECTUS
This summary highlights selected information from this proxy statement/prospectus and does not contain all of the information that may be important to you. To better understand the proposals to be considered at the Special Meeting, including the Business Combination Proposal, whether or not you plan to attend the Special Meeting, we urge you to read this entire proxy statement/prospectus (including the annexes) carefully, including the section entitled “Risk Factors” beginning on page 26. See also the section entitled “Where You Can Find More Information.”

Unless otherwise specified, all share amounts and share calculations: (i) assume no exercise of redemption rights by our public stockholders, (ii) assume that an aggregate of 17.5 million shares of ParentCo Common Stock will be issued to the Liminatus Members as consideration in the Business Combination, and (iii) do not include: (A) any warrants to purchase ParentCo Common Stock that will be outstanding following the Business Combination, or (B) any equity awards that may be issued under the proposed Incentive Plan following the Business Combination.

### Parties to the Business Combination

### IRIS ACQUISITION CORP
Iris is a blank check company, incorporated in Delaware, formed in November 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. Based on its business activities, Iris is a “shell company” as defined under the Exchange Act because it has